cyclic GMP (Compound)

Synonyms:40732-48-7, Monosodium-GMP, Guanosine 3',5'-cyclic monophosphate sodium salt, cyclic gmp, UNII-6WYT1TNR45, Sodium guanosine cyclic monophosphate, Guanosine Monophosphate Monosodium Salt, Cyclic gmp sodium salt, 6WYT1TNR45, GUANOSINE3:5-CYCLICMONOPHOSPHATESODIUMSALT, MFCD00038424, sodium;9-[(4aR,6R,7R,7aS)-7-hydroxy-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]-2-amino-3H-purin-6-one, Guanosine-3':5'-cyclic monophosphate monosodium salt, cGMP sodium salt, EINECS 255-056-0, Cyclic 3',5'-Guanosine Monophosphate Monosodium Salt, 3',5'-cGMP-Na, C10H11N5O7P.Na, DTXSID30860018, Guanosine, cyclic 3',5'-(hydrogen phosphate), monosodium salt, 3',5'-Cyclic GMP monosodium salt, 7032AH, AKOS037646872, AS-71285, Guanosine 3',5'-cyclophosphate monosodium salt, Guanosine 3:5-cyclic monophosphate sodium salt, guanosine 3',5'-cyclic-monophosphate sodium salt, GUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SOD, Q27265640, Guanosine 3',5'-cyclic monophosphate sodium salt, >=99.0% (HPLC), Guanosine 3',5'-cyclic monophosphate sodium salt, >=99% (HPLC), powder, Guanosine 3',5'-cyclic Monophosphate, Sodium Salt - CAS 40732-48-7, sodium (4aR,6R,7R,7aS)-6-(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)-7-hydroxy-2-oxo-hexahydro-2??-furo[3,2-d][1,3,2]dioxaphosphinin-2-olate
Pubchem:PUBCHEM:24316
Id:8f0fc735-5cca-55a4-99ee-1327e8739ca8
Description:nan

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View cyclic GMP's neighborhood in the knowledge graph.

Gene and Drug Landing Page Aggegrator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for cyclic GMP.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with cyclic GMP.

This repository is under review for potential modification in compliance with Administration directives.